Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2018
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.
Abstract readClinical Trial, Phase III
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Intra-arterial infusion of bevacizumab for the treatment of peritoneal metastatic high-grade renal cell carcinoma: a case report.Frontiers in immunology · 2026Article
- Analysis of correlation between dynamic contrast-enhanced ultrasound and angiogenesis activity of renal cell carcinoma.Ultrasound international open · 2025Article
- Stage IA papillary and chromophobe renal cell carcinoma: effectiveness of cryoablation and partial nephrectomy.Insights into imaging · 2024Article
- Investigation of clear cell renal cell carcinoma grades using diffusion-relaxation correlation spectroscopic imaging with optimized spatial-spectrum analysis.The British journal of radiology · 2024Article
- Molecular mechanisms and clinical relevance of endothelial cell cross-talk in clear cell renal cell carcinoma.Upsala journal of medical sciences · 2024Review
- Review
- Construction of a two-gene prognostic model related to ferroptosis in renal cell carcinoma.Translational andrology and urology · 2023Article
- Associations between tumor grade, contrast-enhanced ultrasound features, and microvascular density in patients with clear cell renal cell carcinoma: a retrospective study.Quantitative imaging in medicine and surgery · 2022Article
- Vascular architectural patterns in clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma.Virchows Archiv : an international journal of pathology · 2021Article
- Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma.European radiology experimental · 2021Article
- Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.Journal of neuro-oncology · 2021Article
- Expression of VEGF, CD73 and their relationship with clinical pathology, microvessel density, and prognosis in renal cell carcinoma.Translational andrology and urology · 2020Article
- Angiogenesis in primary colorectal cancer and matched metastatic tissues: Biological and clinical implications for anti-angiogenic therapies.Oncology letters · 2020Article
- High Expression of Galectin-1, VEGF and Increased Microvessel Density Are Associated with MELF Pattern in Stage I-III Endometrioid Endometrial Adenocarcinoma.Journal of pathology and translational medicine · 2019Article
- Specific immune cell and lymphatic vessel signatures identified by image analysis in renal cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.Journal for immunotherapy of cancer · 2019Article
- Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers.The Journal of clinical investigation · 2019Review
- Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma.Current treatment options in oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Lucia B Jilaveanu *Division of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
Maneka Puligandla *Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sarah A Weiss *Division of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
Xin Victoria WangDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Christopher ZitoDivision of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
Keith T FlahertyDivision of Hematology/Oncology, Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.
Marta BoekeDepartment of Urology, Yale University School of Medicine, New Haven, Connecticut.
Veronique NeumeisterDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Robert L CampDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Adebowale AdeniranDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Michael PinsDepartment of Pathology, Advocate Lutheran General Hospital, Park Ridge, Illinois.
Judith ManolaDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Robert S DiPaolaUniversity of Kentucky School of Medicine, Lexington, Kentucky.
Naomi B HaasDepartment of Medicine, Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Harriet M KlugerDivision of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut. Harriet.Kluger@yale.edu.
Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MYale Cancer Center NCTNU10CA180826 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2014 to 2018
$3.4MModels to Predict Prognosis and Benefit from Adjuvant Therapy in Renal Cell CarciR01CA158167 · NCI · YALE UNIVERSITY · PI KLUGER, HARRIET M. · 2011 to 2015
$1.8MA research and training program for junior clinicians in treating metastatic melaK24CA172123 · NCI · YALE UNIVERSITY · PI KLUGER, HARRIET M. · 2013 to 2017
$780kNCI NIH HHS K24 CA172123NCI NIH HHS R01 CA158167NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180826NCI NIH HHS U24 CA196172
Abstract
PubMed holds no abstract for this paper.
Indexed as
Neovascularization, PathologicAdultAgedAntineoplastic AgentsCarcinoma, Renal CellChemotherapy, AdjuvantFemaleHumansKidney NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingPrognosisSorafenibSunitinibAntineoplastic AgentsSorafenibSunitinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.